# Ying Cheng

Source: https://onco.cc/people/cheng-ying/  
OnCo record `cheng-ying` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ying Cheng has led most of the Chinese small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.

## Summary

Principal investigator of ASTRUM-005 (serplulimab plus chemotherapy, JAMA 2022), CAPSTONE-1 (adebrelimab plus chemotherapy, Lancet Oncology 2022) and the benmelstobart plus anlotinib trial in extensive-stage SCLC, as well as Chinese cohorts of global lung cancer studies; chairs CSCO's small cell lung cancer committee.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: 程颖
- Tags: china
- Role: Professor and President, Jilin Cancer Hospital, Changchun
- Specialisms: Small cell lung cancer; Thoracic oncology; Immunotherapy trials

## Sources

- Jilin Cancer Hospital: https://www.jlszlyy.com/
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20Y%5BAuthor%5D%20small%20cell%20lung%20cancer%20Jilin%20Cancer%20Hospital

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Anlotinib](https://onco.cc/drugs/anlotinib/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- institutions: [Jilin Cancer Hospital](https://onco.cc/institutions/jilin-cancer-hospital/)
- trials: [ASTRUM-005](https://onco.cc/trials/astrum-005/), [CAPSTONE-1](https://onco.cc/trials/capstone-1/)

---
JSON: https://onco.cc/api/v1/entities/cheng-ying.json